Belgium-based Galapagos, a drug discovery company, has received a transparency notification from Delta Lloyd, disclosing that it holds a 5.4% interest in the share capital of Galapagos.

Delta Lloyd Levensverzekeringen has disclosed that it holds 1.14 million shares in the share capital of Galapagos, as of September 1, 2008. This is the first notification Galapagos has received from Delta Lloyd Levensverzekeringen. Galapagos had 21.19 million shares outstanding as of September 1, 2008.

Onno Stolpe, CEO of Galapagos, said: We are very pleased to welcome Delta Lloyd as a major institutional shareholder in Galapagos. Delta Lloyd is a highly respected investor, and we are proud of their confidence in the long-term potential of the company.